微卡辅助治疗涂阳肺结核临床疗效分析  

The Clinical Effect Analysis of Mycobacterium Vaccae Adjuvant Therapy on Smear-Positive Pulmonary Tuberculosis

作　　者：谢仲秋[1] 

机构地区：[1]四川省内江市疾病预防控制中心,641100

出　　处：《中国医疗前沿》2012年第21期16-17,共2页China Healthcare Innovation

摘　　要：目的观察和评价微卡辅助治疗涂阳肺结核的临床疗效。方法对初复治涂阳肺结核148例随机分为观察组A、C组及对照组B、D组,A、B组(初治涂阳)分别给予2HRZE/4HR及2HRZE/4HR联合应用微卡治疗,C、D组(复治涂阳)分别给予2HRZE/6HRE及2HRZE/6HRE联合应用微卡治疗。观察治疗后痰菌阴转及病灶吸收情况。结果 A、B组2月末痰检阴转率分别为97.56%、80.49%,病灶吸收率分别为97.56%、80.49%;C、D组2月末痰检阴转率分别为90.91%、63.64%,病灶吸收率分别为90.91%、66.67%,疗程结束时痰检阴转率分别为96.97%、75.76%,病灶吸收率分别为96.97%、75.76%。结论涂阳肺结核在正规化疗的基础上辅助微卡治疗可以明显提高痰菌阴转率及病灶吸收率,不良反应少,使用安全。Objective To observe and evaluate the clinical effect of mycobacterium vaccae adjuvant therapy（MVAT） on smear-positive pulmonary tuberculosis（SPPT）.Methods 148 cases of initial and re-treatment pulmonary tuberculosis（PT） patients were divided into observation groups（A and C） and control groups（B and D） randomly,group A and B（initial treatment） were treated with 2HRZE/4Hr and 2HRZE/4HR combined with mycobacterium vaccae（MV） respectively,meanwhile,group C and D（re-treatment） were treated with 2HRZE/6HRE and 2HRZE/ 6HREcombined with MV respectively.The sputum negative conversion and lesion absorption condition after treatment were observed as the indicators for evaluation.Results The sputumnegative convertion rate（SNCR） of group A and B at the end of 2 months were 97.56% and 80.49% respectively,lesion obsorption rate（LOR） were 97.56%、80.49%,meanwhile,group C and D were 90.91% and 63.64%,90.91% and 66.67%.Conclusion Regular chemotherapy as a basis to combine with the MV treatment can improve the SNCR and LOR significantly.It has the advantage of less adverse reaction and high safety.

关 键 词：涂阳肺结核 微卡 免疫治疗 

分 类 号：R521[医药卫生—内科学]